Research Priorities - Neuroscience
  • Article
  • Jan 21 2021

Florin Despa says that a major scientific goal is to understand whether the same factors that are involved in age-related metabolic disorders such as type-2 diabetes may also play a role in the development and progression of cognitive decline and dementia.

  • Article
  • Nov 24 2020

Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers. Van Eldik is one of only six women from UK that have been awarded this honor and she is the first since 1966.

  • Podcast
  • Nov 20 2020

Dr. Peter Nelson, of the University of Kentucky’s Sanders-Brown Center on Aging, has spent the last 15 years in the Commonwealth helping to lead the fight against Alzheimer’s and dementia inducing brain disease.

  • Article
  • Oct 27 2020

A $2.9 million grant from the NIH is supporting a multidisciplinary team of UK researchers in continuing their work to find therapeutic strategies to resolve neurovascular inflammation and repair blood-brain barrier dysfunction in epilepsy.

  • Article
  • Oct 27 2020

In the sessions for both the scientific and community audience, attendees will have the opportunity to hear clinicians and researchers from UK and other institutions share current findings, trends, and latest updates on dementia and aging disorders.

  • Article
  • Oct 9 2020

Butterfield is among the top 0.007% of scholars worldwide based on authorship of Alzheimer’s-related publications indexed in the PubMed database for the past 10 years. He ranks tenth out of nearly 150,000 scholars worldwide and sixth in the U.S.

  • Article
  • Sep 30 2020

In addition to opening the door to developing blockers of odors, McClintock says this work will help researchers understand why formulating fragrances and flavors with specific properties is so difficult. “Ergo, the oft-used phrase 'the art of perfumery.' Eventually, we will turn this art into science.”

  • Article
  • Sep 23 2020

Selenica says their study is the first to provide a novel pathway and identify potential therapeutic targets for TDP-43 proteinopathies – especially in Alzheimer’s disease and the newly characterized form of dementia known as LATE.

  • Article
  • Aug 25 2020

Through the group's work, they found that the therapeutic targeting of TREM2 using a TREM2-activating antibody leads to the activation of microglia, recruitment of microglia to amyloid plaques, reduced amyloid deposition, and ultimately improved cognition.

  • Article
  • Aug 25 2020

“We used to think that aging-related memory and thinking decline meant one thing: a disease called Alzheimer’s disease. Now we know that the disease we were calling Alzheimer’s disease is actually many different conditions, often in combination."